Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.

导出 LinkOut

翻译打印收藏纠错

第一作者： Takuya,Adachi

第一单位： Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

作者： Takuya,Adachi ^[1] ; Kazuhiro,Nouso ^[1] ; Koji,Miyahara ^[2] ; Atsushi,Oyama ^[3] ; Nozomu,Wada ^[1] ; Chihiro,Dohi ^[1] ; Yasuto,Takeuchi ^[1] ; Tetsuya,Yasunaka ^[1] ; Hideki,Onishi ^[1] ; Fusao,Ikeda ^[1] ; Shinichiro,Nakamura ^[1] ; Hidenori,Shiraha ^[1] ; Akinobu,Takaki ^[1] ; Hiroyuki,Takabatake ^[1] ; Shin-Ichi,Fujioka ^[4] ; Haruhiko,Kobashi ^[5] ; Yoshitaka,Takuma ^[6] ; Shouta,Iwadou ^[3] ; Shuji,Uematsu ^[3] ; Koichi,Takaguchi ^[3] ; Hiroaki,Hagihara ^[7] ; Hiroyuki,Okada ^[8] ; Okayama Liver Cancer Group ^[1]

作者单位： Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. ^[1] Department of Gastroenterology, Okayama City Hospital, Okayama, Japan. ^[2] Department of Internal Medicine, Hiroshima City Hospital, Hiroshima, Japan. ^[3] Department of Gastrointestinal Medicine, Kurashiki Central Hospital, Kurashiki, Japan. ^[4] Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan. ^[5] Department of Internal Medicine, Okayama Red Cross General Hospital, Okayama, Japan. ^[6] Department of Internal Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Japan. ^[7] Department of Internal Medicine, Sumitomo Besshi Hospital, Niihama, Japan. ^[8]

关键词 HCC angiopoietin-2 proangiogenic cytokines sorafenib